Research Study

A Phase 2, 24-Week, Randomized, Double-blind, Placebo-controlled, Multicenter Study, Followed by a 28-Week Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis
Principal Investigator 
Nasreen Khalil

Overview

Body Locations and Systems 
Pulmonary Fibrosis
ClinicalTrials.gov# 
NCT03142191
Status 
Recruiting
Study Start/End 
Aug 1, 2017 to Jun 2, 2021
Locations 
Diamond Health Care Centre
Name/Title 
Giselle Gerdak/Research Coordinator
Phone 
604-875-5091
Email Address 
giselle.gerdak@vch.ca
Purpose of Study 

This is a Phase 2, multicenter, multinational, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, pharmacokinetics (PK), quality of life and exploratory pharmacodynamics (PD) of two treatment doses of CC-90001, 200 mg and 400 mg, compared with placebo, when delivered once daily per os (PO) in subjects with idiopathic pulmonary fibrosis (IPF). This study is designed to assess response to treatment by using measures of lung function, disease progression, fibrosis on radiography, and patient-reported outcomes. It will also assess dose response

Eligibility 

Please see Clinicaltrials.gov

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.